CVKD

Cadrenal Therapeutics (CVKD)

Cadrenal Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:CVKD

1 2 3 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/03	22:00	PR Newswire (US)	Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/05/30	06:27	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/05/23	22:00	PR Newswire (US)	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/05/09	22:00	PR Newswire (US)	Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/05/09	19:23	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/04/12	05:30	PR Newswire (US)	Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/04/09	22:00	PR Newswire (US)	Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/03/11	22:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/03/11	22:00	PR Newswire (US)	Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/03/06	07:24	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/02/26	23:00	PR Newswire (US)	Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/02/15	22:00	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/02/13	06:49	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/02/08	23:00	PR Newswire (US)	Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/01/31	23:00	PR Newswire (US)	Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/01/24	23:00	PR Newswire (US)	Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2024/01/04	23:00	PR Newswire (US)	Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/12/19	23:00	PR Newswire (US)	Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/12/12	23:00	PR Newswire (US)	Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/12/01	06:15	PR Newswire (US)	Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/11/09	23:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/11/09	23:00	PR Newswire (US)	Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/11/09	22:00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/10/24	06:04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/10/10	05:15	PR Newswire (US)	Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/09/09	05:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/09/05	21:00	PR Newswire (US)	Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/09/01	05:05	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/09/01	05:05	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:CVKD	Cadrenal Therapeutics Inc
2023/08/30	21:00	PR Newswire (US)	Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)	NASDAQ:CVKD	Cadrenal Therapeutics Inc